MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

60.55 +0.56 (+0.93%)
Streaming Delayed Price Updated: 2:27 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
1 Mid-Cap Stock Worth Investigating and 2 We Turn Down
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
What Does the Market Think About BioMarin Pharmaceutical? ↗
 
Via Benzinga
News headline image
Demystifying BioMarin Pharmaceutical: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 We Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) shows strong profitability, solid financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill
News headline image
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money ↗
Three magnificent businesses with well-defined catalysts can deliver triple-digit returns amid a historically pricey stock market. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong Fundamentals ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
News headline image
2 Profitable Stocks for Long-Term Investors and 1 to Be Wary Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
News headline image
2 Reasons to Watch BMRN and 1 to Stay Cautious
Over the last six months, BioMarin Pharmaceutical’s shares have sunk to $55.23, producing a disappointing 16.7% loss while the S&P 500 was flat. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
News headline image
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said. 
Via Benzinga
News headline image
Here Are All 6 Stocks I've Bought Through 5 Months of 2025 ↗
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
News headline image
Top movers in Friday's after hours session ↗
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens ↗
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday. 
Via Stocktwits
News headline image
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover ↗
Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children. 
Via Investor's Business Daily
News headline image
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the... 
Via StockStory
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors. 
Via Chartmill
News headline image
1 Healthcare Stock with Competitive Advantages and 2 to Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
News headline image
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta... 
Via StockStory
Topics Artificial Intelligence
News headline image
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know ↗
 
Via Benzinga
News headline image
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s... 
Via StockStory
News headline image
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
2 Cash-Producing Stocks with Exciting Potential and 1 to Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story